Paul Moore
Directeur Technique/Scientifique/R&D chez ZYMEWORKS INC.
Fortune : 62 472 $ au 31/05/2024
Postes actifs de Paul Moore
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ZYMEWORKS INC. | Directeur Technique/Scientifique/R&D | 01/07/2022 | - |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Directeur Technique/Scientifique/R&D | 18/07/2022 | - |
Historique de carrière de Paul Moore
Anciens postes connus de Paul Moore
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MACROGENICS, INC. | Corporate Officer/Principal | 01/04/2008 | 01/07/2022 |
Celera Corp.
 Celera Corp. Medical/Nursing ServicesHealth Services Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA. | Corporate Officer/Principal | 01/05/2005 | 01/04/2008 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - | - |
Formation de Paul Moore
| University of Strathclyde | Undergraduate Degree |
| University of Glasgow | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Royaume-Uni | 3 |
| Canada | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
| Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MACROGENICS, INC. | Health Technology |
| ZYMEWORKS INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Celera Corp.
Celera Corp. Medical/Nursing ServicesHealth Services Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA. | Health Services |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
- Bourse
- Insiders
- Paul Moore
- Expérience
